Study Confirms Benefit of Regorafenib in Previously Treated Metastatic Colorectal Cancer
the ONA take:
According to research presented at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona, Spain, researchers have confirmed that regorafenib is beneficial for the treatment of patients with previously treated metastatic colorectal cancer.
The phase III CORRECT study previously demonstrated a significant improvement in progression-free survival in patients with previously treated metastatic colorectal cancer. For the phase IIIb CONSIGN trial, researchers prospectively assessed the efficacy and safety of regorafenib in patients with pre-treated metastatic colorectal cancer before marketing of the drug was authorized.
The study showed that the estimated progression-free survival was 2.7 months and there were no surprising findings in regard to adverse events.
The CONSIGN trial is significant in that its patient population more closely resembled a real world population of patients compared with the CORRECT trial
"CONSIGN confirms the efficacy and safety data of the randomised phase III CORRECT and CONCUR trials. The merit of CONSIGN is that it translates phase III data into the clinical routine since patients had similar characteristics and pre-treatment to what we see in daily practice," Dirk Arnold, MD, ESMO spokesperson, director of the Department of Medical Oncology, Klinik für Tumorbiologie in Freiburg, Germany, said.
Researchers have confirmed that regorafenib is effective for the treatment of previously treated metastatic colorectal cancer.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|